Campbell & CO Investment Adviser LLC Buys 7,001 Shares of Ascendis Pharma A/S $ASND

Key Points

• Campbell & CO Investment Adviser LLC significantly increased its holdings in Ascendis Pharma A/S by 116% in Q1, now owning shares worth $2,032,000.
• Ascendis Pharma reported better-than-expected quarterly earnings, with an EPS of ($0.93) against a consensus estimate of ($1.42), and revenues of $216.28 million surpassing forecasts of $163.17 million.
• Equities analysts have raised price targets for Ascendis Pharma A/S, with Oppenheimer setting a new price objective of $224.00 and maintaining an "outperform" rating.

Campbell & CO Investment Adviser LLC grew its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 116.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,036 shares of the biotechnology company's stock after buying an additional 7,001 shares during the period. Campbell & CO Investment Adviser LLC's holdings in Ascendis Pharma A/S were worth $2,032,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of ASND. RA Capital Management L.P. boosted its holdings in shares of Ascendis Pharma A/S by 4.1% during the 4th quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company's stock valued at $1,392,221,000 after buying an additional 402,316 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its holdings in shares of Ascendis Pharma A/S by 12.0% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 3,053,824 shares of the biotechnology company's stock valued at $475,970,000 after buying an additional 328,278 shares in the last quarter. Vestal Point Capital LP boosted its holdings in shares of Ascendis Pharma A/S by 108.0% during the 4th quarter. Vestal Point Capital LP now owns 520,000 shares of the biotechnology company's stock valued at $71,588,000 after buying an additional 270,000 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Ascendis Pharma A/S by 4.6% during the 4th quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company's stock valued at $602,910,000 after buying an additional 193,688 shares in the last quarter. Finally, Soleus Capital Management L.P. bought a new stake in shares of Ascendis Pharma A/S during the 4th quarter valued at $19,824,000.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on ASND shares. Cantor Fitzgerald lifted their target price on shares of Ascendis Pharma A/S from $200.00 to $203.00 and gave the stock an "overweight" rating in a report on Friday, August 8th. Wall Street Zen raised shares of Ascendis Pharma A/S from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Royal Bank Of Canada raised their price target on shares of Ascendis Pharma A/S from $210.00 to $230.00 and gave the company an "outperform" rating in a research report on Friday, August 8th. Stifel Nicolaus raised their price target on shares of Ascendis Pharma A/S from $212.00 to $254.00 and gave the company a "buy" rating in a research report on Friday, August 8th. Finally, Citigroup reissued a "buy" rating and set a $290.00 price target (up previously from $243.00) on shares of Ascendis Pharma A/S in a research report on Friday, August 8th. Fifteen investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $243.36.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND traded up $0.37 during midday trading on Friday, hitting $194.27. 357,323 shares of the company's stock traded hands, compared to its average volume of 543,273. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $199.99. The stock has a market capitalization of $11.89 billion, a price-to-earnings ratio of -37.65 and a beta of 0.41. The firm has a fifty day moving average of $180.19 and a 200 day moving average of $166.19.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.49. The business had revenue of $216.28 million for the quarter, compared to analysts' expectations of $163.17 million. On average, equities analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.